Advent France Biotechnology

About The Fund

Advent France Biotechnology is a venture capital firm headquartered in Paris, France, with a clear focus on nurturing healthcare advancements through innovative life sciences startups. Established in 2015 and regulated by the French financial markets authority (AMF) since 2016, the firm is a dedicated supporter of early-stage and seed investments in Europe, the United Kingdom, and the United States. By serving as both entrepreneurs and investors, Advent France Biotechnology, also known as AdBio Partners, prides itself on its strong entrepreneurial spirit and its commitment to aid the progression of healthcare with transformative biotechnology solutions. They specialize in early-stage ventures, zealously investing in groundbreaking discoveries that promise to fulfill unmet medical and clinical needs, particularly in the fields of BioTech, Healthcare, Wellness, Life Sciences, and Oncology. While they are keen on investing in innovative ideas, their strategy extends beyond financial support. AdBio Partners collaborates closely with esteemed research institutions and technology transfer offices across Europe, leveraging an extensive network that includes scientific, industrial partners, and international VC syndicates. The main goal is to source and develop breakthrough medical discoveries in varied therapeutic areas that can drive European life science startups to success. Additionally, they have a strong team equipped with the business, scientific, and financial expertise necessary to identify highly promising therapeutic innovations and to foster sustainable startups alongside scientific founders and academic institutions. Their website also highlights recent involvements in securing seed funding for startups, managerial team promotions, and strategic partnerships aimed at advancing ophthalmic medicines.